AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 08:37:40 2025-07-11 am EDT			5-day change	1st Jan Change
10,497.00 ^GBX	-1.21%		+3.12%	+0.52%

Jul. 10	Britain's FTSE 100 notches record close, buoyed by miners	RE
Jul. 10	Britain's FTSE 100 notches record close, buoyed by miners	RE

ASTRAZENECA : JP Morgan keeps its Buy rating

Published on 05/22/2024 at 00:27, updated on 05/22/2024 at 01:14

In a research note, JP Morgan analyst James Gordon has maintained his recommendation on the stock with a Buy rating. The target price is unchanged at GBX 13000.

Latest news about AstraZeneca PLC

Britain's FTSE 100 notches record close, buoyed by miners	Jul. 10	RE
Britain's FTSE 100 notches record close, buoyed by miners	Jul. 10	RE
Eolas Therapeutics entered new agreement with AstraZeneca	Jul. 10	RE
Record-setting FTSE 100 shines on tariff hope	Jul. 10	AN
Major deals involving U.S. drugmakers and biotechs over the past decade	Jul. 09	RE
Berenberg Lifts AstraZeneca Price Target, Earnings Forecasts on Drug Pipeline Strength	Jul. 09	MT
Berenberg Lifts Price Target on Astrazeneca to $97 From $93, Keeps Buy Rating	Jul. 09	MT
ASTRAZENECA : Deutsche Bank gives a Neutral rating	Jul. 09	ZD
ASTRAZENECA : Berenberg raises target price	Jul. 09	CF
Jefferies says buy BAT and Imperial Brands	Jul. 09	AN
Europe rises despite new US tariff mayhem	Jul. 09	AN
ASTRAZENECA : Berenberg keeps its Buy rating	Jul. 09	ZD
Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn	Jul. 08	RE
Swedish Stocks in North America - Ericsson Drops 1.0 Percent	Jul. 08	FW
The importance of being constantly changing…	Jul. 07
European Union Approves Imfinzi®? for the Treatment of Adult Patients with Resistant Muscle-Invasive Bladder Cancer	Jul. 07	CI
AstraZeneca bladder cancer treatment secures EU approval	Jul. 04	AN
UK Stocks Flat; AstraZeneca Gains on EU Win	Jul. 04	MT
Stocks fade as tariff deadline looms large	Jul. 04	AN
Global markets live: Boeing, Tesla, Nvidia, Stellantis, Commerzbank…	Jul. 04
IAR Soars on Takeover Bid, OMXS30 Index Drops 0.9 Percent	Jul. 04	FW
Health Rounds: Widely used pain drug can be made from plastic waste	Jul. 04	RE
Europe down ahead of US tariff decision deadline	Jul. 04	AN
AstraZeneca's Imfinzi Becomes First Perioperative Bladder Cancer Treatment in EU	Jul. 04	MT
ASTRAZENECA : Gets a Buy rating from UBS	Jul. 04	ZD

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (94.2%). Net sales break down by treatment area between oncology (39.8%), cardiovascular, renal and metabolic diseases (24.4%), respiratory and autoimmune diseases (14.6%), and other (21.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (5.8%). Net sales are distributed geographically as follows: the United Kingdom (8.8%), Europe (21.6%), the United States (40.3%), Americas (5.9%) and Africa/Asia/Australia (23.4%).

Employees

94,300

Sector

Pharmaceuticals

Calendar

Jul. 29 - Q2 2025 Earnings Release

More about the company